Literature DB >> 406837

Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.

K R Comber, M J Basker, C D Osborne, R Sutherland.   

Abstract

The antibacterial activities of ticarcillin, carbenicillin, tobramycin, and gentamicin and of combinations of these antibiotics were measured against Pseudomonas aeruginosa and other gram-negative bacilli in vitro and in experimental mouse infections. Synergistic effects were produced by the penicillin/aminoglycoside combinations in growth inhibition tests and in bactericidal tests against many of the bacteria tested. Combinations of ticarcillin + tobramycin were more active in vitro than carbenicillin + gentamicin against P. aeruginosa but were no more active than the latter against other gram-negative bacilli. Ticarcillin + tobramycin and carbenicillin + gentamicin also demonstrated synergistic activities against P. aeruginosa, Escherichia coli, and Enterobacter cloacae in experimental mouse infection models. Thus, the penicillin/aminoglycoside combinations produced greater protective effects than the individual antibiotics against lethal intraperitoneal infections and also were more effective in reducing kidney counts of viable bacteria and kidney abscess formation in experimental pyelonephritis infections. As was the case in vitro, ticarcillin + tobramycin was more effective than carbenicillin + gentamicin against the experimental P. aeruginosa infections. The results of these in vitro and in vivo studies suggest that combined therapy with ticarcillin and tobramycin may be warranted in the treatment of serious infections due to P. aeruginosa and Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406837      PMCID: PMC352110          DOI: 10.1128/AAC.11.6.956

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Interactions between aminoglycoside antibiotics and carbenicillin or ticarillin.

Authors:  H A Holt; J M Broughall; M McCarthy; D S Reeves
Journal:  Infection       Date:  1976       Impact factor: 3.553

2.  Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

Authors:  J E McLaughlin; D S Reeves
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

3.  Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin.

Authors:  J Klastersky; A Henri; L Vandenborre
Journal:  Am J Med Sci       Date:  1973-07       Impact factor: 2.378

4.  Laboratory and clinical conditions for gentamicin inactivation by carbenicillin.

Authors:  L J Riff; G G Jackson
Journal:  Arch Intern Med       Date:  1972-12

5.  Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas.

Authors:  V T Andriole
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Antimicrobial effectiveness ofkanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods.

Authors:  J Klastersky; B Nyamubeya; L Vandenborre
Journal:  J Med Microbiol       Date:  1974-11       Impact factor: 2.472

7.  Antimicrobial activity of the carbenicillin-gentamicin combination against gram-negative bacilli.

Authors:  J Klastersky; G Swings; D Daneau
Journal:  Am J Med Sci       Date:  1970-12       Impact factor: 2.378

8.  Effect of carbenicillin, gentamicin, and their combination on experimental Pseudomonas aeruginosa urinary tract infection.

Authors:  L Konícková; V Prát
Journal:  J Clin Pathol       Date:  1971-03       Impact factor: 3.411

9.  Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.

Authors:  M F Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

10.  Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; W H Greene; S C Schimpff; F M Calia; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

View more
  22 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

4.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

5.  Pseudomonas endophthalmitis associated with scleral necrosis.

Authors:  K H Tarr; I J Constable
Journal:  Br J Ophthalmol       Date:  1980-09       Impact factor: 4.638

6.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Ticarcillin bioassay.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

Review 9.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 10.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.